Snapshot from Jun 26, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Serum Institute of India / Gilead Sciences

Serum Institute of India & Gilead Sciences

1 shared events · Importance 3 · Last updated May 30, 2026

Importance
3
Shared Events
1
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
Shared Events (1)
30
Accidents
Unknown Event
Serum Institute of India: The Serum Institute of India is manufacturing doses of a vaccine candidate built on the University of Oxford/AstraZeneca platform, which could be used for clinical trials against the Bundibugyo ebolavirus.
Gilead Sciences: Gilead Sciences' antiviral drug remdesivir and experimental drug obeldesivir are being prioritized for clinical trials to treat or prevent the Bundibugyo ebolavirus, indicating its significant role in potential therapies.
May 18, 2026 · 505 articles
NEWSDESK
Explore this relationship live

Track how Serum Institute of India and Gilead Sciences interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.